Last checked at 20 May 2022 07:05
PRESS RELEASE
20 May 2022
Genflow Biosciences Plc
("Genflow" or "the Company")
Notice of Annual General Meeting
Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, is pleased to announce that it will hold its Annual General Meeting ("AGM") at 09:00am on Tuesday 14th June 2022 at the offices of Westend Corporate LLP, 48 Warwick Street, London, W1B 5AW.
The Notice of the AGM ("Notice") and 2022 Form of Proxy are now available on the Company website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.
As announced on 29 April 2022, the Company's Annual Report and Accounts for the year ended 31 December 2021 is also available on the website and has, where applicable, also been posted to shareholders.
For further information please contact:
Genflow Biosciences Plc | |
Dr Eric Leire Chief Executive | via Tancredi +44 203 434 2330 |
Clear Capital Markets Ltd | |
Corporate Broker Jonathan Critchley Keith Swann | +44 203 869 6086 +44 203 897 0981 |
Tancredi Intelligent Communication Media Relations | |
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio | +44 7957 549 906 +44 7449 226 720 +44 7838 029 970 genflowbio@tancredigroup.com |
About Genflow
Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.
Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.
To learn more visit www.genflowbio.com
-Ends-